Citations

Clear

9 citation(s) found for "Rosa, Alan De la".

Prolonged Water‐Only Fasting Followed by a Whole‐Plant‐Food Diet Promotes Fat‐Free Mass Recovery and Continued Fat Mass Loss in Adults With Overweight or Obesity
Gabriel, Sahmla , Ncube, Mackson, Goldman, David , Goldhamer, Alan , Myers, Toshia R. , Myers, Toshia R , Scharf, Eugene

Mayo Clinic

Obesity Science & Practice | August 5, 2025 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/osp4.70086 | PMID 40765844 Get It

ABSTRACTIntroductionConventional weight‐loss strategies often result in inadequate fat loss, poor sustainability, and unintended lean mass loss. Prolonged water‐only fasting followed by dietary change may offer an effective alternative, but its impact on body composition remains underexplored.MethodsThis secondary analysis utilized dual‐energy X‐ray absorptiometry (DXA) to assess changes in fat‐free mass (FFM), fat mass (FM), and bone mineral content (BMC) in adults [median (IQR) age: 62 (15) years with overweight or obesity. Participants underwent a median (IQR) of 14 (6) days of water‐only fasting, followed by 6 (3) days of food reintroduction with a whole‐plant‐food diet and a subsequent maintenance period of 45 (5) days. Study visits occurred at baseline and at the end of each period.ResultsAt end of fasting, FFM accounted for 74% of total BW lost during fasting. However, at the follow‐up visit, the median (IQR) percentage change in total BW, FFM, FM, and visceral adipose tissue (VAT) mass from baseline was −8.2 (5.2), −4.4 (5.6), −14.7 (8.9), −15.8 (12.8) %, respectively. At follow‐up, FM loss accounted for 67% of the total BW lost. BMC remained unchanged across all study visits.ConclusionsThis protocol produced sustained FM loss, specifically VAT mass, and FFM recovery, suggesting it may support effective weight management.
Prolonged Water-Only Fasting Followed by a Whole-Plant-Food Diet Is a Potential Long-Term Management Strategy for Hypertension and Obesity
Zeiler, Evelyn , Gabriel, Sahmla , Ncube, Mackson, Thompson, Natasha , Newmire, Daniel E., Scharf, Eugene , Goldhamer, Alan , Myers, Toshia R. , Newmire, Daniel , Scharf, Eugene L , Goldhamer, Alan C , Myers, Toshia R

Mayo Clinic

Nutrients | November 20, 2024 | Volume: 16 | Issue: 22 | Pages: 3959

10.3390/nu16223959 | PMID 39599745 Get It

Objective: This single-arm, pre–post interventional trial (clinicaltrials.gov, NCT04515095) investigates the safety, feasibility, and potential effectiveness of prolonged water-only fasting followed by a whole-plant-food diet in the long-term management of hypertension and other cardiometabolic disorders. Methods: Safety was assessed based on adverse events (AEs) that were recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Feasibility was assessed based on retention rate, ability to complete minimal fast length, and intervention acceptability. Twenty-nine participants with stage 1 and 2 hypertension and without type 2 diabetes were enrolled from a residential fasting center. Results: Study retention was 100% at the end of the refeed and 93% at the six-week follow-up visit. Median (range) fasting and refeeding duration were 11 (7–40) and 5 (3–17) days, respectively, and 90% of participants were able to complete at least 7 days of fasting. The majority of AEs were mild (grade 1) and transient and there were no higher-grade or serious AEs. At the end of the intervention, median systolic/diastolic blood pressure had normalized to below 130/80 mmHg, body weight reduced by >5%, and anti-hypertensive medication was completely discontinued. These results were sustained for at least six weeks and potentially up to one year. Conclusions: Our data suggest that the intervention may be a feasible, well-tolerated, low-risk option for lowering and managing high blood pressure, excess body weight, and other cardiometabolic disorders in people with stage 1 and 2 hypertension.
The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes
Ghusn, Wissam , Fansa, Sima , Añazco, Diego , Tama, Elif , Cifuentes, Lizeth , Gala, Khushboo , Rosa, Alan De la , Sacoto, Daniel , Feris, Fauzi , Hurtado, Daniela, De la Rosa, Alan, Ghusn, Wissam , Anazco, Diego , Campos, Alejandro , Acosta, Andrés

Mayo Clinic

Diabetes, Obesity and Metabolism | March 12, 2024 | Volume: 26 | Issue: 6 | Pages: 2167-2175

10.1111/dom.15523 | PMID 38469598 Get It

Abstract Aims To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those who were AOM‐naïve. Materials and Methods We performed a retrospective study in patients with overweight or obesity taking semaglutide for weight loss for a duration of 3 to 12 months. Our primary endpoint was assessment of percentage of total body weight loss (TBWL) in patients who started semaglutide as their first AOM (AOM‐naïve) compared to those who started semaglutide and had previously taken another AOM (non‐AOM‐naïve). The secondary outcome was a comparison of the proportions of patients achieving ≥5%, ≥10%, ≥15% and ≥20% TBWL between the groups. Our endpoints were analysed using independent t ‐tests and ANOVA/ANCOVA for continuous variables and Pearson's test for categorical variables. Results This study included 305 patients. Outcomes of semaglutide treatment were superior in AOM‐naïve patients ( n = 231) compared to non‐AOM‐naïve patients ( n = 74) at 3 (6.3% vs. 3.8%), 6 (10.6% vs. 6.7%), 9 (14.0% vs. 9.1%) and 12 months (14.3% vs. 10.6%; p < 0.0001 at 3, 6 and 9 months, and p = 0.01 at 12 months). A greater proportion of patients in the AOM‐naïve group achieved a TBWL ≥ 15% (48% vs 21%; p = 0.02) and ≥20% (27% vs 4% p < 0.01) at 12 months. Conclusion The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes in comparison to patients who were AOM‐naïve.
S1648 Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study
Fansa, Sima , Tama, Elif , Rosa, Alan De la , Nicolalde, Bryan , Cifuentes, Lizeth , Sacoto, Daniel , Feris, Fauzi , Gala, Khushboo, Ghusn, Wissam , Añazco, Diego , Campos, Alejandro , Gala, Khushboo , Calderon-Lopez, Gerardo , Hashem, Anas , Hurtado, Maria D. , Acosta, Andrés

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S1234-S1235

10.14309/01.ajg.0000956232.19702.5a Get It

S1632 Effect of Changes in Gastric Emptying and Low-Calorie Phenotype Tailored Diet on Weight Loss: Results From a 12-week Clinical Trial
Cifuentes, Lizeth , Feris, Fauzi , Sacoto, Daniel , Rosa, Alan De la , Ghusn, Wissam , Campos, Alejandro , Hurtado, Maria D. , Acosta, Andrés

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S1223-S1224

10.14309/01.ajg.0000956168.75138.f0 Get It

S1485 Semaglutide Outcomes in Non-Alcoholic Fatty Liver Disease: A Multi-Centered Real-World Study
Fansa, Sima , Tama, Elif , Nicolalde, Bryan , Gala, Khushboo, Cifuentes, Lizeth , Rosa, Alan De la , Sacoto, Daniel , Feris, Fauzi , Ghusn, Wissam , Añazco, Diego , Gala, Khushboo , Campos, Alejandro , Acosta, Andrés

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S1127-S1128

10.14309/01.ajg.0000955580.73643.8b Get It

A Six-Week Follow-Up Study on the Sustained Effects of Prolonged Water-Only Fasting and Refeeding on Markers of Cardiometabolic Risk
Gabriel, Sahmla , Ncube, Mackson, Zeiler, Evelyn , Thompson, Natasha , Karlsen, Micaela, Goldman, David , Glavas, Zrinka, Beauchesne, Andrew R. , Scharf, Eugene , Goldhamer, Alan , Myers, Toshia R. , Karlsen, Micaela , Goldhamer, Alan C , Scharf, Eugene L , Karlsen, Micaela C

Mayo Clinic

Nutrients | October 17, 2022 | Volume: 14 | Issue: 20 | Pages: 4313

10.3390/nu14204313 | PMID 36296997 Get It

(1) Background: Chronic inflammation and insulin resistance are associated with cardiometabolic diseases, such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Therapeutic water-only fasting and whole-plant-food refeeding was previously shown to improve markers of cardiometabolic risk and may be an effective preventative treatment but sustained outcomes are unknown. We conducted a single-arm, open-label, observational study with a six-week post-treatment follow-up visit to assess the effects of water-only fasting and refeeding on markers of cardiometabolic risk. (2) Methods: Patients who had voluntarily elected and were approved to complete a water-only fast were recruited from a single-center residential medical facility. The primary endpoint was to describe changes to Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) scores between the end-of-refeed visit and the six-week follow-up visit. Additionally, we report on changes in anthropometric measures, blood lipids, high-sensitivity C-reactive protein (hsCRP), and fatty liver index (FLI). Observations were made at baseline, end-of-fast (EOF), end-of-refeed (EOR), and six-week follow-up (FU). (3) Results: The study enrolled 40 overweight/obese non-diabetic participants, of which 33 completed the full study protocol. Median fasting, refeeding, and follow-up lengths were 14, 6, and 45 days, respectively. At the FU visit, body weight (BW), body mass index (BMI), abdominal circumference (AC), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low-density lipoprotein (LDL), hsCRP, and FLI were significantly decreased from baseline. Triglycerides (TG) and HOMA-IR scores, which had increased at EOR, returned to baseline values at the FU visit. (4) Conclusion: Water-only fasting and whole-plant-food refeeding demonstrate potential for long-term improvements in markers of cardiovascular risk including BW, BMI, AC, SBP, DBP, blood lipids, FLI, and hsCRP.
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Ghusn, Wissam , Rosa, Alan De la , Sacoto, Daniel , Cifuentes, Lizeth , Campos, Alejandro , Feris, Fauzi , De la Rosa, Alan, Hurtado, Maria Daniela , Ghusn, Wissam , Campos, Alejandro , Hurtado, Maria D. , Acosta, Andrés

Mayo Clinic

JAMA Network Open | September 19, 2022 | Volume: 5 | Issue: 9 | Pages: e2231982

10.1001/jamanetworkopen.2022.31982 | PMID 36121652 Get It

ImportanceNo retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg).ObjectiveTo study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity.Design, Setting, and ParticipantsThis cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.ExposuresWeekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months.Main Outcomes and MeasuresThe primary end point was the percentage of weight loss. Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months.ResultsThe study included 175 patients (132 women [75.4%]; mean [SD] age, 49.3 [12.5] years; mean [SD] BMI, 41.3 [9.1]) in the analysis at 3 months and 102 patients at 6 months. The mean (SD) weight loss after 3 months was 6.7 (4.4) kg, equivalent to a mean (SD) weight loss of 5.9% (3.7%) (P &lt; .001), and the mean (SD) weight loss after 6 months was 12.3 (6.6) kg, equivalent to a mean (SD) weight loss of 10.9% (5.8%) (P &lt; .001 from baseline). Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more. Patients with type 2 diabetes had a lower mean (SD) percentage weight loss at 3 and 6 months compared with those without type 2 diabetes: 3.9% (3.1%) vs 6.3% (3.7%) at 3 months (P = .001) and 7.2% (6.3%) vs 11.8% (5.3%) at 6 months (P = .005).Conclusions and RelevanceThe results of this cohort study suggest that weekly 1.7-mg and 2.4-mg doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials. Studies with longer periods of follow-up are needed to evaluate prolonged weight loss outcomes.
The Effects of Prolonged Water-Only Fasting and Refeeding on Markers of Cardiometabolic Risk
Scharf, Eugene , Zeiler, Evelyn , Ncube, Mackson, Kolbe, Patricia, Hwang, Su‐Yeon , Goldhamer, Alan , Myers, Toshia R. , Scharf, Eugene L

Mayo Clinic

Nutrients | March 13, 2022 | Volume: 14 | Issue: 6 | Pages: 1183

10.3390/nu14061183 | PMID 35334843 Get It

(1) Background: Cardiometabolic disease, including insulin resistance, hyperlipidemia, and hypertension, are major contributors to adverse health outcomes. Fasting has gained interest as a nonpharmacological therapeutic adjunct for these disorders. (2) Methods: We conducted a prospective, single-center study on the effects of prolonged water-only fasting followed by an exclusively whole-plant-food refeeding diet on accepted measures of cardiovascular risk and metabolic health. Participants were recruited from patients who had voluntarily elected to complete a water-only fast in order to improve their overall health according to an established protocol at an independent, residential medical center. Median fasting and refeed lengths were 17 and 8 days, respectively. The primary endpoint was to describe the mean glucose tolerance as indicated by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) scores at baseline, end-of-fast (EOF), and end-of-refeed (EOR) visits. Secondary endpoints were to describe the mean weight, body mass index (BMI), abdominal circumference (AC), systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid panel, and high-sensitivity C-reactive protein (hsCRP) at the same time points. (3) Results: The study enrolled 48 overweight/obese non-diabetic participants, of which 26 completed the full study protocol. At the EOF visit, the median SBP, AC, low-density lipoprotein (LDL), and hsCRP were decreased and triglycerides (TG) and HOMA-IR scores were increased. Conclusion: Prolonged water-only fasting and whole-plant-food refeeding holds potential as a clinical therapy for cardiometabolic disease but increased TG and HOMA-IR values after refeeding necessitate further inquiry.